COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

SYL040012. Tolerance and Effect on Intraocular Pressure in Subjects With Intraocular Pressure (IOP) >= 21 mm Hg

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01227291
Recruitment Status : Completed
First Posted : October 25, 2010
Last Update Posted : September 27, 2012
Information provided by (Responsible Party):
Sylentis, S.A.

Brief Summary:
The aim of this study is to evaluate the tolerance and effect on unmedicated subjects with elevated IOP.

Condition or disease Intervention/treatment Phase
Glaucoma Ocular Hypertension Drug: SYL040012 Phase 1 Phase 2

Detailed Description:
The aim of this study is to evaluate the tolerance and effect on unmedicated subjects with elevated IOP. An unmedicated subject is considered a person without any IOP/glaucoma treatment at least one month before recruitment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Study With SYL040012. Tolerance and Effect on Intraocular Pressure in Subjects With IOP >= 21 mm Hg.
Study Start Date : October 2010
Actual Primary Completion Date : March 2012
Actual Study Completion Date : September 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: SYL040012
SYL040012 Ophthalmic drop administration
Drug: SYL040012
SYL040012 ophthalmic drops, daily single dose administration
Other Name: No additional names

Primary Outcome Measures :
  1. Tolerance on ocular surface (ocular and conjunctiva) [ Time Frame: 7 days + 24 hours ]
    Local Tolerance and ocular surface(cornea and conjunctival) on the area of administration 24 hours after last administration of multiple dose during 7 days of administration. It will be performed using a slit lamp which will be performed before, during and after the administration at established times. Adverse events will be registered and the determination of subjective tolerance will use the visual analogical scale (VAS) in cases where a subjects refers them.

Secondary Outcome Measures :
  1. Tolerance, Adverse events, Pharmacokinetics and effect [ Time Frame: 11 days ]

    Local Tolerance on the area of administration at 1 hour and 96 hours after the last administered dose: corneal pachymetry, rest of anterior exploration of the eye, visual acuity, eye fundus, clinical exam (including physical exploration, vital signs, analytical blood and urine test, and ECG.

    Other parameters: analytics, VAS evaluation, Evaluation of adverse event appearance Pharmacokinetics: SYL040012 blood absorption will be evaluated after topical ocular administration Effect on IOP

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Both genders.
  • >/= 18 years of age with elevated IOP with OAG diagnosis.
  • Subjects must provide signed informed consent prior to participation in any study-related procedures
  • IOP >/= 21 mmHg and < 30 mmHg in three different assessment days.
  • Normal Ocular test (in both eyes):

    • Visual field: 24-2 or equivalent
    • Normal OCT
    • BCVA: >/= 0,5 (20/40) Snellen scale, or </=0.3 LogMar.
    • Normal Schirmer Test .
    • Normal funduscopy.

Exclusion Criteria:

  • Pregnant or breastfeeding females or those with a positive pregnancy test. Females of childbearing potential who will not use a medically acceptable contraceptive method from selection and during the hole study.
  • Current relevant disease, including respiratory disease, cardiovascular, endocrine, neurological, hematological, renal, neoplastic, hepatopathy, gastrointestinal distress, hypertension or infectious acute processes.
  • Previous chronic processes or with rebound characteristics that could interfere with the study according to the investigator's judgment.
  • Having used betablockers and corticoids sporadically in the last 15 days whichever the route of administration.
  • Previous eye refractive surgery
  • Subjects with visual alteration with more than 3 dioptres for hypermetropy and/or astigmatism.
  • Use of contact lenses during the last 7 days before starting the treatment.
  • Subjects who has participated in a clinical trial during the past 2 months before study entry.
  • Analytic alterations medically relevant, at investigator judgment.
  • Positive results in test drug abuse during selection period.
  • Subjects with at least 2 visual fields or fiber layer measured in two different days abnormals
  • History of ocular infection or inflammation within the past 3 months
  • Pachymetry(in the middle of the cornea) >600 microm or < 500 microm.
  • Subjects with IOP associated to close angle glaucoma
  • History of chronic or severe acute ocular disease (i.e. scleritis, uveitis, blepharitis, conjunctivitis or herpes simplex virus)
  • History of intolerance to any of the components of the drug formulation
  • Subjects with previous iridotomy with IOP related with close angle glaucoma.
  • Previous ocular surgery in glaucoma
  • Corneal refractive surgery (e.g., keratotomy, PRK, LASIK, etc)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01227291

Layout table for location information
Clinica Universidad Navarra
Pamplona, Navarra, Spain, 31008
Hospital Universitario Ramón y Cajal
Madrid, Spain, 28034
Sponsors and Collaborators
Sylentis, S.A.
Layout table for investigator information
Principal Investigator: Javier Moreno, MD, PhD Clinica Universidad de Navarra
Principal Investigator: Francisco Muñoz, MD, PhD Hospital Universitario Ramon y Cajal

Layout table for additonal information
Responsible Party: Sylentis, S.A. Identifier: NCT01227291    
Other Study ID Numbers: SYL040012_II
First Posted: October 25, 2010    Key Record Dates
Last Update Posted: September 27, 2012
Last Verified: September 2012
Keywords provided by Sylentis, S.A.:
beta inhibitor
Additional relevant MeSH terms:
Layout table for MeSH terms
Ocular Hypertension
Eye Diseases